{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:36Z","timestamp":1791669096206,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["shmpublications.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hospital Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Importance<\/jats:title><jats:p>Alcohol use disorder (AUD) significantly increases hospitalizations and death. US Food and Drug Administration (FDA)\u2010approved medications for AUD are underutilized. Gabapentinoids are not FDA\u2010approved for AUD but are frequently prescribed by physicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the association of acamprosate and gabapentinoids on healthcare utilization and total mortality in patients with AUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two propensity score (PS)\u2010matched retrospective cohort studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Veterans diagnosed with AUD (years 2003\u20132021) initiating acamprosate or gabapentinoids in an AUD\u2010related encounter and not on chronic opioid therapy (AUD\u2010cohort). Another PS\u2010cohort of veterans who were hospitalized for AUD diagnoses (AUD\u2010admission cohort). Subgroup analysis included people with chronic obstructive lung diseases, opioid use, and age categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes<\/jats:title><jats:p>Co\u2010primary outcomes were admission for alcohol withdrawal (AW\u2010admission) and annual rate of acute care events. Secondary outcome was total mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We matched 16,072 pairs of acamprosate and gabapentinoid users in AUD\u2010cohort. AW\u2010admission occurred in 35.4% of the acamprosate users and 30.0% of the gabapentinoid users (odds ratio [OR]: 1.28, 95% confidence interval [95% CI]: 1.22\u20131.34). Annual rate of acute care events in acamprosate and gabapentinoid users were 1.84 and 1.64, respectively (coefficient of regression [<jats:italic>\u03b2<\/jats:italic>]: 0.20, 95% CI: 0.12\u20130.28). There was no difference in total mortality (hazard ratio: 0.96, 95% CI: 0.91\u20131.005). In subgroup analysis, acamprosate use was associated with less total mortality in subgroups of people using opioids and older than 60 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gabapentinoids are associated with reduced AW\u2010admission and lower annual rates of acute care events compared to acamprosate. Gabapentinoids may offer a viable alternative for AUD in carefully selected populations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jhm.70033","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:57:56Z","timestamp":1743325076000},"page":"919-934","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder"],"prefix":"10.1002","volume":"20","author":[{"given":"Raj","family":"Shah","sequence":"first","affiliation":[{"name":"Education Services, Orlando VA Healthcare System Orlando Florida USA"},{"name":"University of Central Florida\/HCA Florida Healthcare Greater Orlando Florida USA"},{"name":"Department of Internal Medicine University of Central Florida College of Medicine Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten A.","family":"Zelneronok","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Orlando VA Healthcare System Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Henriquez","sequence":"additional","affiliation":[{"name":"Education Services, Orlando VA Healthcare System Orlando Florida USA"},{"name":"University of Central Florida\/HCA Florida Healthcare Greater Orlando Florida USA"},{"name":"Department of Internal Medicine University of Central Florida College of Medicine Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-3716","authenticated-orcid":false,"given":"Ishak A.","family":"Mansi","sequence":"additional","affiliation":[{"name":"Education Services, Orlando VA Healthcare System Orlando Florida USA"},{"name":"University of Central Florida\/HCA Florida Healthcare Greater Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"National Institute on Alcohol Abuse and Alcoholism.Alcohol\u2010Related Emergencies and Deaths in the United States. National Institute on Alcohol Abuse and Alcoholism (NIAAA)."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4308"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13559"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2017.02.014"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.36518\/2689-0216.1243"},{"key":"e_1_2_10_7_1","first-page":"879","article-title":"Comparison of healthcare utilization among patients treated with alcoholism medications","volume":"16","author":"Mark TL","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3387"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2022-001899"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102102"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2997"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1108"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102623"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000954908.27192.4f"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109671"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14655"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2751"},{"key":"e_1_2_10_18_1","unstructured":"VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders;2021. Accessed November 2024.https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPG.pdf"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2012.01937.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-015-0053-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.00165"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0200200403"},{"key":"e_1_2_10_23_1","unstructured":"LeuvenE SianesiB. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching common support graphing and covariate imbalance testing. 2003. Accessed March 2025.http:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173482"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109400"},{"key":"e_1_2_10_26_1","unstructured":"FDA Drug Safety Communication. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin Gralise Horizant) and pregabalin (Lyrica Lyrica CR). December 19 2019. Accessed June 6 2024.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin"},{"key":"e_1_2_10_27_1","unstructured":"US Department of Veterans Affairs Information Resource Center.VIReC Research User Guide: PSSG Geocoded Enrollee Files 2015 ed.US Department of Veterans Affairs Health Services Research & Development Service Information Resource Center;2016."},{"key":"e_1_2_10_28_1","unstructured":"Veterans Benefits Administration. Regional Offices Websites. Accessed February 6 2025.https:\/\/benefits.va.gov\/benefits\/offices.asp"},{"key":"e_1_2_10_29_1","unstructured":"VA Information Resource Center. VIReC VHA Managerial Cost Accounting (MCA) Historical Stop Codes. U.S. Dept. of Veterans Affairs Health Services Research and Development Service VA Information Resource Center; April 1 2022."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.11950"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0249"},{"key":"e_1_2_10_32_1","unstructured":"UpToDate Lexidrug. Gabapentin: drug information. Accessed June 6 2024.https:\/\/www.uptodate.com\/contents\/gabapentin-drug-information?search=gabapentin&selectedTitle=1%7E150&usage_type=panel&display_rank=1&kp_tab=drug_general&source=panel_search_result#references"},{"key":"e_1_2_10_33_1","unstructured":"Micromedix. Pergabalin: Non\u2010FDA uses. Accessed June 6 2024.https:\/\/www-micromedexsolutions-com.foyer.swmed.edu\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.DoIntegratedSearch?navitem=topHome&isToolPage=true"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3019"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14408"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2023.1218737"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2023.025"},{"key":"e_1_2_10_40_1","unstructured":"MillerL. Statistics on veterans and substance abuse. 2021. Accessed June 6 2024.https:\/\/veteranaddiction.org\/resources\/veteran-statistics\/"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3934"}],"container-title":["Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhm.70033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:41:35Z","timestamp":1760625695000},"score":1,"resource":{"primary":{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/10.1002\/jhm.70033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/jhm.70033"],"URL":"https:\/\/doi.org\/10.1002\/jhm.70033","archive":["Portico"],"relation":{},"ISSN":["1553-5592","1553-5606"],"issn-type":[{"value":"1553-5592","type":"print"},{"value":"1553-5606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2024-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}